iScience (May 2018)

Mitochondria-Targeted Honokiol Confers a Striking Inhibitory Effect on Lung Cancer via Inhibiting Complex I Activity

  • Jing Pan,
  • Yongik Lee,
  • Gang Cheng,
  • Jacek Zielonka,
  • Qi Zhang,
  • Martina Bajzikova,
  • Donghai Xiong,
  • Shirng-Wern Tsaih,
  • Micael Hardy,
  • Michael Flister,
  • Christopher M. Olsen,
  • Yian Wang,
  • Ole Vang,
  • Jiri Neuzil,
  • Charles R. Myers,
  • Balaraman Kalyanaraman,
  • Ming You

Journal volume & issue
Vol. 3
pp. 192 – 207

Abstract

Read online

Summary: We synthesized a mitochondria-targeted honokiol (Mito-HNK) that facilitates its mitochondrial accumulation; this dramatically increases its potency and efficacy against highly metastatic lung cancer lines in vitro, and in orthotopic lung tumor xenografts and brain metastases in vivo. Mito-HNK is >100-fold more potent than HNK in inhibiting cell proliferation, inhibiting mitochondrial complex ǀ, stimulating reactive oxygen species generation, oxidizing mitochondrial peroxiredoxin-3, and suppressing the phosphorylation of mitoSTAT3. Within lung cancer brain metastases in mice, Mito-HNK induced the mediators of cell death and decreased the pathways that support invasion and proliferation. In contrast, in the non-malignant stroma, Mito-HNK suppressed pathways that support metastatic lesions, including those involved in inflammation and angiogenesis. Mito-HNK showed no toxicity and targets the metabolic vulnerabilities of primary and metastatic lung cancers. Its pronounced anti-invasive and anti-metastatic effects in the brain are particularly intriguing given the paucity of treatment options for such patients either alone or in combination with standard chemotherapeutics. : Natural Product Chemistry; Immunology; Medicinal and Aromatic Plants Subject Areas: Natural Product Chemistry, Immunology, Medicinal and Aromatic Plants